Nextrials has found a new partner to adopt its clinical trials software, which is tailored for the iPad. InClin, a clinical research organization, plans to use Nextrials' Prism software to speed the start of trials and push down costs of drug development.
India's biotech industry is better known for its contract research operations than novel drug development. But Advinus Pharma, a biotech company supported by the Tata group, is helping to change all that.
Under its private equity masters at Bain Capital and TPG Capital, Quintiles has been rapidly beefing up its clinical-to-commercial outsourcing operations around the globe. Now Bloomberg reports that the makeover may lead to one very big cash-out as Quintiles execs ponder filing an IPO.
Call it the bionic drug R&D group. Without scads of scientists on hand, AstraZeneca's virtual neuroscience unit relies heavily on information technologies to automate some of the heavy lifting of managing a pipeline of drugs for neurological and psychiatric disorders. In an interview with FierceBiotech IT, AZ research information head John Reynders described the tech platforms supporting the research group.
The global contract research group PRA has opened a second outpost in China as demand for clinical trials in Asia soars and the U.S.-based CRO's pharma customers set up their own operations in the country.
Over the past year we've been treated to a number of reports underscoring just how rarely amazing biomedical studies can actually be independently reproduced in the lab. Now a Silicon Valley startup has begun offering scientists a chance to see if their work can pass the validation test and speed up the drug development process.
Wheeling and dealing its way around the globe, Quintiles has snapped up a genomics testing operation in its own back yard in North Carolina to help keep up with the revolution underway in the development of personalized medicines.
Parexel International is reaching out to small and mid-sized biopharma companies, launching a wing of its business that specializes in suiting the needs of companies outside the big time.
Back in 2008, Covance inked a 10-year CRO deal with Eli Lilly, buying out some of the pharma giant's labs in central Indiana for $50 million and agreeing to provide early-stage research support in a pact that helped create a new template for strategic clinical research agreements.
The multinational CRO Quintiles is stepping up its game in China's fast-growing drug development arena with plans to partner with a local clinical research group as it builds a new regional headquarters facility for itself in Shanghai.